ClinicalTrials.gg
TerminatedNCT03778073Updated Aug 22, 2022

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

A Phase 1 interventional study of Cosibelimab and Cosibelimab + Ublituximab + Bendamustine combination in B-cell Non Hodgkin Lymphoma and Richter's Transformation, sponsored by TG Therapeutics, Inc.. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-22.

Sponsored by TG Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic/Business Decision

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
279th of 380
18 · median 37
Started
2019
with 21 others
Phase 1
161 of 398
34 open now
Registered
205th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 279th largest by enrollment of the 380 interventional ones that give a count, is one of 22 that started in 2019, is one of 161 in phase 1, and was the 205th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

Read the detailed description

This study will evaluate the safety profile, pharmacokinetics, and efficacy of single-agent cosibelimab as well as the combination of Cosibelimab + Ublituximab + Bendamustin.

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma
  • Richter's Transformation

Keywords

  • relapsed or refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed B-cell non-Hodgkin lymphoma (NHL).
  • and adequate organ function as specified in the protocol

Key Exclusion Criteria:

  • Prior therapy with an , anti-PD-L1, anti-PD-L2, or prior therapy with bendamustine.
  • Subjects receiving cancer therapy or drug within 21 days of Cycle 1 Day 1.
  • Prior stem cell transplant within 3 months
  • Active or
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort A

    Cosibelimab (TG-1501) single-agent

    Drug: Cosibelimab

  • Experimental
    Cohort B

    Cosibelimab + Ublituximab + Bendamustine combination

    Drug: Cosibelimab + Ublituximab + Bendamustine combination

  • Experimental
    Cohort C

    Cosibelimab + Ublituximab + Bendamustine combination

    Drug: Cosibelimab + Ublituximab + Bendamustine combination

Interventions

  • Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle

  • DrugCosibelimab + Ublituximab + Bendamustine combination

    Drug pages: Cosibelimab · Ublituximab · Bendamustine

    Cosibelimab (Intravenous infusion): Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles; Ublituximab (Intravenous infusion): Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles; Bendamustine (Intravenous infusion): Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.

  • DrugCosibelimab + Ublituximab + Bendamustine combination

    Drug pages: Cosibelimab · Ublituximab · Bendamustine

    Cosibelimab (Intravenous infusion): Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles; Ublituximab (Intravenous infusion): Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles; Bendamustine (Intravenous infusion): Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.

06

What researchers measure

Primary outcomes

  1. Adverse Events That Are Related to Treatment

    Number of Participants With Treatment-Related Adverse Events, any potential abnormal laboratory results and any dose-limiting toxicities

    Time frame: 6 months of therapy

Secondary outcomes

  1. Overall Response Rate

    Objective response in subjects treated with interventions

    Time frame: Up to 12 months

07

Study locations

9 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Tucson, Arizona 85711, United States
  • TG Therapeutics Investigational Trial Site
    Fayetteville, Arkansas 72703, United States
  • TG Therapeutics Investigational Trial Site
    Peoria, Illinois 61615, United States
  • TG Therapeutics Investigational Trial Site
    Fort Wayne, Indiana 46804, United States
  • TG Therapeutics Investigational Trial Site
    Fairway, Kansas 64154, United States
  • TG Therapeutics Investigational Trial Site
    Louisville, Kentucky 40207, United States
  • TG Therapeutics Investigational Trial Site
    Charlotte, North Carolina 28262, United States
  • TG Therapeutics Investigational Trial Site
    Seattle, Washington 98108, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in May 2022, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 19, 2018
StartActual
Apr 17, 2019
Primary completionActual
May 3, 2022
CompletionActual
Aug 1, 2022
Last update
Aug 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03778073
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Apr 17, 2019
Primary completion
May 3, 2022
Completion
Aug 1, 2022
Last update
Aug 22, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cosibelimab · Ublituximab · Bendamustine

Start the discussion